PANACEABIOPharmaceuticals
Panacea Biotec Ltd — Cash Flow Statement
₹296.05
-2.65%
Panacea Biotec Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -77.68 Cr | -79.41 Cr | -463.40 Cr | -120.96 Cr | — |
| Repayment Of Debt | 0.00 | -0.24 Cr | -14.77 Cr | -786.36 Cr | — |
| Issuance Of Debt | 0.00 | 0.00 | 0.00 | 0.30 Cr | — |
| Capital Expenditure | -50.31 Cr | -82.88 Cr | -40.95 Cr | -12.51 Cr | — |
| End Cash Position | 82.13 Cr | 47.17 Cr | 39.85 Cr | 50.35 Cr | — |
| Beginning Cash Position | 47.17 Cr | 39.85 Cr | 50.35 Cr | 52.08 Cr | — |
| Effect Of Exchange Rate Changes | 0.01 Cr | 0.00 | -40000.00 | -0.01 Cr | — |
| Changes In Cash | 34.95 Cr | 7.32 Cr | -10.49 Cr | -1.73 Cr | — |
| Financing Cash Flow | -2.66 Cr | -2.81 Cr | -18.37 Cr | -1.18K Cr | — |
| Interest Paid Cff | -2.66 Cr | -2.57 Cr | -3.60 Cr | -389.79 Cr | — |
| Net Issuance Payments Of Debt | 0.00 | -0.24 Cr | -14.77 Cr | -786.07 Cr | — |
| Net Short Term Debt Issuance | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Short Term Debt Issuance | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Long Term Debt Issuance | 0.00 | -0.24 Cr | -14.77 Cr | -786.07 Cr | — |
| Long Term Debt Payments | 0.00 | -0.24 Cr | -14.77 Cr | -786.36 Cr | — |
| Long Term Debt Issuance | 0.00 | 0.00 | 0.00 | 0.30 Cr | — |
| Investing Cash Flow | 64.98 Cr | 6.66 Cr | 430.33 Cr | 1.28K Cr | — |
| Net Other Investing Changes | 1.83 Cr | 1.59 Cr | — | — | — |
| Interest Received Cfi | 7.71 Cr | 8.37 Cr | 11.56 Cr | 3.28 Cr | — |
| Dividends Received Cfi | 0.00 | 0.01 Cr | 0.50 Cr | — | — |
| Net Investment Purchase And Sale | 105.17 Cr | 72.89 Cr | 419.71 Cr | -532.20 Cr | — |
| Sale Of Investment | 321.59 Cr | 423.51 Cr | 1.29K Cr | 517.16 Cr | — |
| Purchase Of Investment | -216.42 Cr | -350.62 Cr | -868.07 Cr | -1.05K Cr | — |
| Net PPE Purchase And Sale | -49.73 Cr | -76.20 Cr | -1.44 Cr | -10.51 Cr | — |
| Sale Of PPE | 0.58 Cr | 6.68 Cr | 39.51 Cr | 2.00 Cr | — |
| Purchase Of PPE | -50.31 Cr | -82.88 Cr | -40.95 Cr | -12.51 Cr | — |
| Operating Cash Flow | -27.37 Cr | 3.47 Cr | -422.45 Cr | -108.45 Cr | — |
| Taxes Refund Paid | -0.96 Cr | -2.51 Cr | -2.48 Cr | -403.70 Cr | — |
| Change In Working Capital | -8.59 Cr | 10.23 Cr | -336.91 Cr | 300.86 Cr | — |
| Change In Inventory | -35.74 Cr | 24.16 Cr | 10.63 Cr | -38.58 Cr | — |
| Change In Receivables | -65.84 Cr | -24.46 Cr | -23.90 Cr | -34.56 Cr | — |
| Other Non Cash Items | -45.26 Cr | -49.47 Cr | -6.56 Cr | 175.74 Cr | — |
| Provisionand Write Offof Assets | 1.25 Cr | 0.57 Cr | -25.48 Cr | -2.23 Cr | — |
| Depreciation And Amortization | 34.81 Cr | 36.71 Cr | 39.12 Cr | 43.78 Cr | — |
| Depreciation | 34.81 Cr | 36.71 Cr | 38.85 Cr | 43.02 Cr | — |
| Gain Loss On Investment Securities | -2.45 Cr | -3.38 Cr | -1.95 Cr | -10000.00 | — |
| Net Foreign Currency Exchange Gain Loss | 0.76 Cr | 0.13 Cr | 3.53 Cr | 2.39 Cr | — |
| Gain Loss On Sale Of PPE | -0.45 Cr | 4.56 Cr | -2.30 Cr | -70000.00 | — |
| Net Income From Continuing Operations | -7.95 Cr | 1.48 Cr | 12.80 Cr | 1.45K Cr | — |
| Amortization Cash Flow | — | 2.35 Cr | 0.28 Cr | 0.76 Cr | — |
| Net Business Purchase And Sale | — | — | 0.00 | 1.82K Cr | 5.59 Cr |
| Sale Of Business | — | — | 0.00 | 1.82K Cr | 5.59 Cr |
| Gain Loss On Sale Of Business | — | — | -102.66 Cr | -1.68K Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | — | — | 0.01 Cr | -0.11 Cr |
| Short Term Debt Payments | — | — | — | 0.00 | -3.57 Cr |
| Issuance Of Capital Stock | — | — | — | — | 0.00 |
| Net Common Stock Issuance | — | — | — | — | 0.00 |
| Common Stock Issuance | — | — | — | — | 0.00 |
| Purchase Of Business | — | — | — | — | 0.00 |
| Change In Other Current Liabilities | — | — | — | — | 51.30 Cr |
| Change In Other Current Assets | — | — | — | — | -26.44 Cr |
| Change In Payable | — | — | — | — | 23.51 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Panacea Biotec Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.